Combination of insulin with triazine derivatives

A pharmaceutical composition comprising insulin in combination with at least one compound of formula (I) and/or physiologically acceptable salts thereof, wherein the compound of formula (I) is defined as follows:

• in which
• R1, R2 each, independently of one another, denote H or A,
• R3, R4 each, independently of one another, denote H, A, alkenyl having 2-6 C atoms, alkynyl having 2-6 C atoms, Ar or Het,
• R5, R6 each, independently of one another, denote H, A, (CH2)nAr, (CH2)mOAr, (CH2)mOA or (CH2)mOH,
• R5 and R6 together also denote alkylene having 2, 3, 4 or 5 C atoms, in which one CH2 group may be replaced by O, NH or NA and/or in which 1 H atom may be replaced by OH,
• Ar denotes phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, OH, COOH, COOA, CN, NH2, NHA, NA2, SO2A and/or COA,
• Het denotes a mono-, bi- or tricyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, OH, OA, NH2, (CH2)nAr, NHA, NA2, COOH, COOA and/or ═O (carbonyl oxygen),
• A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by F, or cyclic alkyl having 3-7 C atoms,
• Hal denotes F, Cl, Br or I,
• m denotes 1, 2, 3, 4, 5 or 6, and
• n denotes 0, 1 or 2.